盐酸曲马多(Tramadol Hydrochloride) - 药物靶点：NET x μ opioid receptor_在研适应症：慢性疼痛，疼痛，癌症疼痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Abidol、Tramadol、Tramadol hydrochloride (JP17/USP)

+ [64]

靶点

NET x μ opioid receptor

作用方式

抑制剂、激动剂

作用机制

NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、μ opioid receptor激动剂(μ-阿片受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Nippon Shinyaku Co., Ltd.

多多药业有限公司

+ [4]

非在研机构

Bausch Health Americas, Inc.

Janssen Pharmaceuticals, Inc.

Purdue Pharma LP

+ [5]

权益机构

Fortress Biotech, Inc.Mundipharma KK

Revogenex Ltd.

+ [2]

最高研发阶段批准上市

首次获批日期

日本 (1978-03-10),

癌症疼痛术后疼痛

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C16H26ClNO2

InChIKeyPPKXEPBICJTCRU-NDFJEYLFSA-N

CAS号36282-47-0

关联

550

项与盐酸曲马多相关的临床试验

NCT07032558

/ Recruiting临床1期IIT

A Randomized, Open-label, Single Oral Dose, Two-period, Cross-over Trial to Evaluate the Pharmacokinetics of Pelubiprofen-Tramadol (DW-1021) Controlled Release Film Coated Tablets (Pelubiprofen 45mg-Tramadol 45.9mg Salt) (Test Drug) in Comparison With the Co-administration of Each of Pelubi CR 45mg Controlled Release Film Coated Tablets (Pelubiprofen 45mg) and Zytram CR 75mg Controlled Release Film Coated Tablets (Tramadol HCl 75mg) in Healthy Adult Vietnamese Male Subjects Under Fasting Condition

This is a Phase 1, randomized, open-label, single-dose, two-period, cross-over study to evaluate the pharmacokinetics (PK) of DW-1021, a fixed-dose combination tablet containing Pelubiprofen 45 mg and Tramadol 45.9 mg (as a salt), in healthy adult Vietnamese male volunteers. The study compares DW-1021 with the co-administration of two reference drugs: Pelubi CR 45 mg (Pelubiprofen) and Zytram CR 75 mg (Tramadol HCl), under fasting conditions.
A total of 14 eligible participants will be randomly assigned to receive either the test drug followed by the reference drugs, or vice versa, with a 14-day washout period between the two dosing periods. Blood samples will be collected over a 48-hour period after each administration to evaluate drug concentrations. The main purpose is to assess and compare the rate and extent of absorption (Cmax, AUC) of the test and reference products.
The study is sponsored by Haiphong University of Medicine and Pharmacy in collaboration with Daewon Pharmaceutical Co., Ltd. It is conducted under ethical approval by the National Ethics Committee in Biomedical Research of Vietnam.

开始日期2025-09-20

申办/合作机构

Daewon Pharmaceutical Co., Ltd.

NCT07040709

/ RecruitingN/AIIT

Investigation of the Effectiveness of Adductor Canal Block and Suprainguinal Fascia Iliaca Block in Patients Planned for Total Knee Arthroplasty

In total knee arthroplasty, the effectiveness of some peripheral nerve blocks in postoperative pain control has been investigated, with conflicting results reported. The primary aim of this study is to evaluate the effects of the suprainguinal fascia iliaca plane block, which is routinely performed in our clinic for postoperative pain management, and the adductor canal block in patients undergoing total knee arthroplasty under spinal anesthesia. Patients scheduled for total knee arthroplasty under spinal anesthesia will be randomly assigned using computer-generated randomization into two groups: the adductor canal block group (Group A) and the suprainguinal fascia iliaca plane block group (Group S). The nerve blocks will be performed by a single investigator according to the assigned group. Postoperative follow-up assessments will be conducted and recorded by a different investigator who is blinded to which nerve block was performed.

开始日期2025-06-08

申办/合作机构

Gaziosmanpasa Universitesi

CTRI/2025/04/085003

/ Not yet recruiting临床4期IIT

A Prospective, Single blinded Randomized Controlled Trial to evaluate the effectiveness of intravenous Tramadol for labor analgesia in low-risk pregnant patients in labor - NIL

开始日期2025-04-28

申办/合作机构-

100 项与盐酸曲马多相关的临床结果

登录后查看更多信息

100 项与盐酸曲马多相关的转化医学

登录后查看更多信息

100 项与盐酸曲马多相关的专利（医药）

登录后查看更多信息

9,882

项与盐酸曲马多相关的文献（医药）

2025-12-31·Canadian Journal of Pain-Revue Canadienne de la Douleur

Comparison of opioid use among long-term care residents in Ontario and Alberta, Canada: A multi-jurisdictional, repeated cross-sectional study

Article

作者: Li, Zhiyin ; Maxwell, Colleen J. ; Hogan, David B. ; Maclagan, Laura C. ; Gruneir, Andrea ; Campitelli, Michael A. ; Chen, Xueyi ; Youngson, Erik ; Iaboni, Andrea ; Bronskill, Susan E.

Background:

Exploring regional variation in opioid use for pain among long-term care (LTC) residents may help identify modifiable factors associated with suboptimal prescribing practices.

Aims:

We aimed to compare recent trends in prevalent opioid use and higher risk prescribing among LTC residents in Ontario and Alberta, and to examine variation in opioid trends across resident subgroups within each province.

Methods:

Utilizing comparable linked clinical and health administrative databases for LTC residents (aged >65) in each province, we examined trends in monthly use of any opioid, specific drug types and formulations, high daily doses (≥90 Morphine Equivalents), and concurrent use with a benzodiazepine or gabapentinoid. Prevalence ratios comparing change in opioid measures, overall and across resident subgroups, from the first (March 2015) to last study (March 2022) months were estimated using age-sex adjusted log-binomial regression models.

Results:

Opioid prevalence (any, select types, long-acting formulations, high daily doses) was consistently higher among Ontario residents whereas concurrent use with a benzodiazepine or gabapentinoid was higher among Alberta residents. Overall use remained stable in Ontario but increased by 23% in Alberta LTC. In both provinces, there were significant decreases in higher risk opioid prescribing over time, including concurrent use with benzodiazepines, but also significant increases in the concurrent use with gabapentinoids and tramadol use (Alberta only).

Conclusions:

Although both provinces showed trends toward more appropriate opioid use in LTC, the factors driving observed provincial differences in opioid prescribing and the rise in concurrent opioid and gabapentinoid use among residents, warrant further investigation.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Abuse and misuse of tramadol in patients with non-oncologic pain in a region of Southern Europe

Article

作者: Cereza, G. ; Pérez-Cano, F. J. ; Rius, P. ; Rio-Aigé, K. ; Perelló, M. ; Rabanal, M.

Background:

Tramadol can cause dependence even within the recommended dose range. Its use has increased recently, especially in patients with chronic pain, and although a growing body of literature identifies a non-therapeutic use, patterns of misuse of tramadol is so far limited.

Methods:

Two-year observational and cross-sectional study (January 2020 - December 2021) was conducted in 75 community pharmacies from Catalonia. To estimate the potential abuse and misuse of tramadol by patients visiting community pharmacy, and to establish the demographic characteristics of the tramadol users, a validated questionnaire based on the Finch criteria was designed. A total of 251 cases were registered.

Results:

Data show that women were more involved (56.6%) and the highest proportion was found in the age interval of 46-65 years (42.6%). The combination of tramadol and paracetamol was reported in 54.6% of the cases and 73.7% corresponded to immediate-release tablets. In 93.6% of the cases, the request was preceded by previous use. Conversely, young men showed a higher non-prescription request for tramadol, reporting acute pain (p < 0.05). These results indicate that there is non-therapeutic use among patients who visit community pharmacies for information on two profiles.

Conclusion:

This study shows that being an aged woman and suffering from chronic pain seems to involve a risk of generating dependence on tramadol. Likewise, a suspicion of recreational use of tramadol by young people has also been identified. There is a need to investigate how to manage chronic pain, given its complexity and take into account the risk of misuse that may come with tramadol. The involvement of characteristics such as gender as well as the pharmaceutical form in the development of tramadol misuse also needs to be analysed deeply. It is mandatory to evaluate the criteria for prescribing tramadol and initiatives to improve the knowledge of the health professionals and the population.

2025-11-01·CURRENT CANCER DRUG TARGETS

Controversial Role of Opioids: From Pain Control to Cancer Recurrence in Breast Cancer

Article

作者: Khan, Gyas ; Zhang, Liming ; Maqbool, Mudasir ; Hussain, Md Sadique

Opioids are widely used for pain management in breast cancer patients; however, their influence on tumor progression and recurrence remains controversial. Opioid receptors-mu (MOR), delta (DOR), and kappa (KOR)-play diverse roles in cancer biology, modulating tumor growth, im-mune responses, and angiogenesis. MOR activation is associated with increased proliferation, Epi-thelial-Mesenchymal Transition (EMT), and immunosuppression, contributing to an aggressive tu-mor phenotype. Conversely, KOR exhibits tumor-suppressive properties, reducing angiogenesis via VEGF inhibition. Emerging preclinical evidence suggests that opioids, particularly morphine, may facilitate breast cancer progression by enhancing cancer cell migration, angiogenesis, and immune evasion. Genetic variations in opioid receptor pathways, such as the OPRM1 A118G polymorphism, further complicate the opioid-cancer relationship, demonstrating population-dependent effects on pa-tient outcomes. In contrast, tramadol has shown potential immune-protective effects by preserving Natural Killer (NK) cell function and inhibiting adrenergic signaling; fentanyl and sufentanil exhibit variable impacts on tumor biology, necessitating further investigation. Clinical studies, however, re-main inconclusive regarding opioids' direct contribution to breast cancer recurrence, highlighting the need for targeted research. Opioid-sparing analgesic strategies, including multimodal pain manage-ment, regional anesthesia, and immunomodulatory agents, offer promising alternatives to mitigate potential oncogenic risks while ensuring adequate pain relief. Future studies integrating single-cell transcriptomics and tumor microenvironment analyses will be critical in elucidating the molecular impact of opioids in breast cancer. Personalized pain management approaches tailored to genetic and clinical profiles may optimize oncological outcomes while preserving analgesic efficacy.

207

项与盐酸曲马多相关的新闻（医药）

2025-08-25

·中国药闻

澳大利亚修订托莫西汀药品说明书警示5-羟色胺综合征和小儿磨牙症

药物警戒快讯近日，国家药品不良反应监测中心网站发布了2025年第8期药物警戒快讯，汇总了澳大利亚、英国、欧盟发布的4条药品安全性信息，分别是：澳大利亚修订含对乙酰氨基酚药品说明书警示焦谷氨酸酸中毒引起的高阴离子间歇代谢性酸中毒、澳大利亚修订托莫西汀药品说明书警示5-羟色胺综合征和小儿磨牙症、英国更新丙戊酸盐生殖风险安全教育材料、欧盟评估男性服用丙戊酸钠与子代神经发育障碍风险的新证据。澳大利亚修订托莫西汀药品说明书警示5-羟色胺综合征和小儿磨牙症 2025年6月26日，澳大利亚治疗产品管理局（TGA）发布6月份的产品安全信息更新情况，其中对已批准上市的托莫西汀药品说明书中安全性信息进行更新，警示5-羟色胺综合征和小儿磨牙症。涉及更新的说明书相关章节如下：【警告和注意事项】　　在“5-羟色胺综合征”小标题下新增警告：　　据报道，托莫西汀与其他5-羟色胺药物[例如，5-羟色胺去甲肾上腺素再摄取抑制剂（SNRIs）、选择性5-羟色胺再摄取抑制剂（SSRIs）、其他 SNRIs、曲坦类药物、阿片类药物以及三环类和四环类抗抑郁药]联合使用后出现了5-羟色胺综合征。如果确需将托莫西汀与5-羟色胺药物联合使用，及时识别5-羟色胺综合征的症状非常重要。这些症状可能包括精神状态改变、自主神经不稳定、神经肌肉异常和/或胃肠道症状。若怀疑出现5-羟色胺综合征，应根据症状的严重程度考虑减少剂量或停止治疗。　　在“攻击行为或敌意”小标题下新增额外警告：已报告涉及儿科患者的严重病例，包括身体攻击行为、威胁行为以及伤害他人的想法。应告知接受托莫西汀治疗的儿科患者的家属和护理人员，如果注意到情绪或行为模式发生显著变化，特别是在开始治疗或改变剂量后，应立即提醒医护人员。对于出现行为改变的患者，医生应评估是否需要调整剂量或停止治疗。【药物相互作用】　　在“5-羟色胺综合征”小标题下新增相互作用：　　托莫西汀应谨慎与5-羟色胺类药物、选择性5-羟色胺再摄取抑制剂 (SSRIs)、5-羟色胺去甲肾上腺素再摄取抑制 (SNRIs)、阿片类药物（如曲马多）以及四环类或三环类抗抑郁药联合使用，因为会增加发生5-羟色胺综合征（一种可能危及生命的病症）的风险。【不良反应】　　在儿科患者中出现磨牙症，频率未知。【药物过量】　　5-羟色胺综合征。（澳大利亚TGA网站）原文链接： https://www.tga.gov.au/news/safety-updates/product-information-safety-updates-june-2025 来源：国家药品不良反应监测中心网站

上市批准

2025-08-21

·ETPharma

Injecting crushed painkillers 'direct path to death': Haryana Narcotics Control Bureau chief

Chandigarh: With an intensified crackdown on narcotics sharply cutting supply lines in Haryana, the squeeze is pushing addicts toward dangerous substitutes -- injecting crushed painkillers and prescription tablets, officials said. O P Singh, head of the Haryana State Narcotics Control Bureau (HSNCB), on Thursday said addicts are reportedly crushing and injecting tablets such as Tramadol , Tapentadol , and Pregabalin and warned that it was a "direct path to death." Medical experts say this misuse can trigger blood clotting, cardiac arrest, and sudden death within minutes. Singh, a DGP-rank officer, said, "Improvised drug substitutes like injecting crushed tablets are not only hazardous, they are lethal. Misuse of such medicines can stop the heart instantly. No high is worth a life." Enforcement data from January to July 2025 showed an intensified crackdown on narcotics, with 2,161 FIRs being registered during the period, compared to 2,022 in the corresponding period last year, a 6.87 per cent rise. Seizures increased with 267 commercial quantity cases being booked against last year's 238 (12.18 per cent rise), while 1,493 intermediate quantity cases were recorded compared to 1,142 in 2024 (30.74 per cent rise). Arrests jumped 35.21 per cent, from 2,684 to 3,629, and inter-state arrests rose to 293 from 175, a 36.57 per cent increase. Preventive detentions climbed from eight in 2024 to 39 this year (79.48 per cent rise). Multi-accused cases almost doubled, rising from 574 to 1,030 (79.44 per cent increase). "These numbers show that our grip on the supply network is tightening," another senior officer of the bureau said, adding, "We are targeting traffickers at every level, from local peddlers to interstate cartels". The HSNCB is coupling enforcement with prevention, according to officials. Between January and July, 698 awareness programmes were held, reaching over 1.15 lakh participants. The 'Sports for Youth' programme covered 4,270 villages and engaged 2.8 lakh young people, Singh said. The bureau maintains that the war against drugs is not just about seizures but also about protecting citizens from dangerous improvisations born of scarcity. Last week, Singh appealed to the people to play an active role by reporting any drug-related activities on the national helpline number -- 1993. Singh recently launched a podcast series to bring the people closer to the state's battle against drugs by offering real, unfiltered stories from ground operations.

2025-08-08

·国家药品监督管理局

2025年08月08日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CYZB2402236疏风定痛丸呼伦贝尔松鹿制药有限公司————2025年08月05日2CXSS2300100阿达木单抗注射液武汉生物制品研究所有限责任公司国药准字S202500412025年08月05日3CXSS2400051度拉糖肽注射液山东博安生物技术股份有限公司国药准字S202500422025年08月05日4CXSS2400052度拉糖肽注射液山东博安生物技术股份有限公司国药准字S202500432025年08月05日5CXSS2400053度拉糖肽注射液山东博安生物技术股份有限公司国药准字S202500442025年08月05日6CXSS2400054度拉糖肽注射液山东博安生物技术股份有限公司国药准字S202500452025年08月05日7CYHB2201012国硫辛酸注射液山东新时代药业有限公司国药准字H202581542025年08月06日8CYHB2401665注射用头孢哌酮钠舒巴坦钠湖南科伦制药有限公司国药准字H202581562025年08月07日9CYHB2450325盐酸异丙嗪注射液遂成药业股份有限公司————2025年08月07日10CYHB2450337盐酸利多卡因注射液山东圣鲁制药有限公司————2025年08月07日11CYHB2450385盐酸曲马多注射液多多药业有限公司————2025年08月07日12CYHB2450551普伐他汀钠片第一三共制药（上海）有限公司————2025年08月06日13CYHB2450552普伐他汀钠片第一三共制药（上海）有限公司————2025年08月06日14CYHB2500736枸橼酸爱地那非片悦康药业集团股份有限公司————2025年08月07日15CYHB2501142奥拉帕利片南京方生和医药科技有限公司————2025年08月07日16CYHB2501450硝酸异山梨酯注射液湖北美林药业有限公司————2025年08月07日17CYHB2501458维生素B1片浙江兄弟药业有限公司————2025年08月07日18CYHB2501459复方氨酚烷胺片郑州卓峰制药有限公司————2025年08月07日19CYHB2501471玛巴洛沙韦片桂林南药股份有限公司————2025年08月07日20CYHB2501476马来酸奈拉替尼片江苏亚虹医药科技股份有限公司————2025年08月07日21CYHB2501480生理氯化钠溶液兰西哈三联制药有限公司————2025年08月07日22CYHS2303349、CYHB2500074盐酸特比萘芬喷雾剂浙江百代医药科技有限公司国药准字H202550822025年08月05日23CYHS2401261盐酸氨溴索注射液多多药业有限公司国药准字H202550832025年08月05日24CYHS2401668丙酸氯倍他索搽剂江苏知原药业股份有限公司国药准字H202550842025年08月05日25CYZB2501109普乐安片甘肃河西制药有限责任公司————2025年08月05日26CYZB2501458黄藤素分散片湖南湘雅制药有限公司————2025年08月05日27CYZB2501459金刚藤分散片湖南湘雅制药有限公司————2025年08月05日28JXSS2400004埃万妥单抗注射液西安杨森制药有限公司国药准字SJ202500052025年08月05日29JYHB2400557来特莫韦片默沙东研发（中国）有限公司————2025年08月07日30JYHB2400558来特莫韦片默沙东研发（中国）有限公司————2025年08月07日31JYHB2400561来特莫韦注射液默沙东研发（中国）有限公司————2025年08月07日32JYHB2400562来特莫韦注射液默沙东研发（中国）有限公司————2025年08月07日33JYHB2500272尼莫地平注射液简柏特（佛山）信息技术服务有限公司————2025年08月07日

申请上市

100 项与盐酸曲马多相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01355	盐酸曲马多	N02AX02	DB00193

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性疼痛	美国	Bausch Health Cos., Inc.	2005-09-08
疼痛	中国	多多药业有限公司	1994-01-01
癌症疼痛	日本	Nippon Shinyaku Co., Ltd.	1978-03-10
术后疼痛	日本	Nippon Shinyaku Co., Ltd.	1978-03-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
早泄	临床3期	奥地利	Bausch Health Americas, Inc.	2009-08-01
早泄	临床3期	比利时	Bausch Health Americas, Inc.	2009-08-01
早泄	临床3期	法国	Bausch Health Americas, Inc.	2009-08-01
早泄	临床3期	德国	Bausch Health Americas, Inc.	2009-08-01
早泄	临床3期	荷兰	Bausch Health Americas, Inc.	2009-08-01
早泄	临床3期	西班牙	Bausch Health Americas, Inc.	2009-08-01
早泄	临床3期	瑞典	Bausch Health Americas, Inc.	2009-08-01
腰痛	临床3期	-	Bausch Health Americas, Inc.	2000-11-01
膝关节炎	临床3期	-	Bausch Health Americas, Inc.	2000-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04752384 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 放射性口腔黏膜炎	20	Oral Mucositis (OM) Pain App+Tramadol+Buprenorphine	艱簾膚窪觸範餘鏇廠選 = 鑰襯顧顧襯壓蓋窪淵築遞蓋積構鏇蓋廠蓋夢蓋 (構齋壓網構鏇鬱遞鬱積, 膚鏇獵獵網壓獵糧鏇衊 ~ 製鏇鏇觸獵窪憲壓憲獵) 更多	-	2025-04-20
NCT05716763 (CTgov)	临床1期	-	24	Tramadol Hydrochloride 5 MG/ML Oral Solution (Tramadol Hydrochloride 5mg/mL Oral Solution (IMP 08P1902F0))	製鑰憲獵醖鑰觸願艱鑰(醖鬱獵鹽鬱積齋構窪餘) = 築窪築夢範艱範蓋鏇築願顧構糧遞憲觸獵製範 (艱鹹膚獵築艱遞鏇窪顧, 53.01) 更多	-	2024-12-16
				Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r)) (Tramadol Hydrochloride 100mg/mL Oral Solution (Contramal(r)))	製鑰憲獵醖鑰觸願艱鑰(醖鬱獵鹽鬱積齋構窪餘) = 夢鑰膚夢簾鹽蓋顧憲鏇願顧構糧遞憲觸獵製範 (艱鹹膚獵築艱遞鏇窪顧, 36.02) 更多
NCT04694300 (CTgov)	临床4期	口颌疾病 \| 急性疼痛	30	Tramadol+Naproxen (Naproxen Sodium)	獵簾衊齋鑰廠艱鏇壓顧(積鑰襯範蓋築選醖築餘) = 夢構鹽鏇鹽獵選襯壓廠鑰蓋鏇鏇憲製鬱憲觸淵 (築鬱廠鏇夢構衊夢遞窪, 壓鹽獵鹽艱繭醖遞選鬱 ~ 憲糧鬱餘鹹積鹽餘鏇鹽) 更多	-	2024-05-16
				Tramadol+Acetaminophen (Acetaminophen)	獵簾衊齋鑰廠艱鏇壓顧(積鑰襯範蓋築選醖築餘) = 觸廠鬱繭網獵獵衊範構鑰蓋鏇鏇憲製鬱憲觸淵 (築鬱廠鏇夢構衊夢遞窪, 夢構選糧觸膚膚繭鹽壓 ~ 獵餘網壓壓鑰選顧餘窪) 更多
NCT01517711 (CTgov)	临床4期	创伤后应激障碍	40	Tramadol	鑰糧製夢鏇衊齋願襯範(鑰壓選選積願夢繭窪簾) = 遞繭醖選簾顧範鹽簾憲膚觸蓋餘夢艱積觸鹹醖 (醖襯廠築壓淵觸鑰顧構, 構淵繭築襯鏇齋淵遞範 ~ 遞構糧齋鹽醖簾選膚鹽) 更多	-	2022-08-31
NCT04813016 (Pubmed \| J Pain Res)	临床2/3期	-	100	Early Bupivacaine/Tramadol	糧襯醖艱齋顧糧窪鹽膚(艱夢網網繭膚艱蓋構鹽) = 願繭鹽夢窪鹽艱鬱糧獵獵夢鑰鑰築繭獵簾糧鹹 (選窪獵築範廠製艱壓願, 2.0)	-	2022-01-01
				Late Bupivacaine/Tramadol	糧襯醖艱齋顧糧窪鹽膚(艱夢網網繭膚艱蓋構鹽) = 糧鏇繭觸壓衊願積鹽鏇獵夢鑰鑰築繭獵簾糧鹹 (選窪獵築範廠製艱壓願, 0.8)
NCT03472469 (MAST, CTgov)	临床4期	创伤后疼痛	1,561	Opioids+Tramadol+Pregabalin+Naproxen+Acetaminophen PO+Acetaminophen IV/PO+Ketorolac+Lidocaine+Celebrex+Gabapentin (Original MMPR - Descending Dose Arm)	憲醖築簾壓鹽遞窪獵淵(蓋壓鬱壓衊淵衊獵糧觸) = 壓獵顧齋鬱獵膚鏇齋鹽遞顧艱選構築醖醖餘衊 (鏇構構糧遞築鹽鏇鏇網, 築醖壓膚艱衊構艱鹽廠 ~ 鬱顧壓繭醖衊壓鹽鏇夢) 更多	-	2021-06-10
				Opioids+Naproxen+Acetaminophen PO+Ketorolac+Lidocaine+Gabapentin (MAST MMPR - Escalating Dose Arm)	憲醖築簾壓鹽遞窪獵淵(蓋壓鬱壓衊淵衊獵糧觸) = 醖窪餘艱壓遞觸醖鏇範遞顧艱選構築醖醖餘衊 (鏇構構糧遞築鹽鏇鏇網, 鹹鬱壓廠鏇憲鹹淵淵顧 ~ 繭壓淵觸顧顧齋憲願範) 更多
NCT03395808 (CTgov)	临床3期	术后疼痛	251	Tramadol	築糧夢選壓製糧廠壓遞(遞網餘鏇鹽衊齋餘築膚) = 膚願構夢觸襯簾糧鏇遞鬱醖壓艱膚蓋襯餘鏇製 (廠積顧簾鬱鑰範願蓋積, 鬱醖蓋餘淵獵淵壓蓋範 ~ 淵衊膚遞積繭鹹襯憲夢) 更多	-	2021-03-09
NCT03309163 (Pubmed \| Front Med (Lausanne))	临床4期	产后抑郁症	1,230	Tramadol PCIA	築顧繭獵艱遞築積窪醖(構夢膚廠糧鬱範壓衊壓) = 構齋醖鑰鹽齋餘築鏇衊製糧醖齋鹽構淵顧膚築 (鑰糧襯襯範構蓋衊構網 )	-	2021-01-01
				Hydromorphone PCIA	築顧繭獵艱遞築積窪醖(構夢膚廠糧鬱範壓衊壓) = 築膚觸選鏇衊觸繭齋構製糧醖齋鹽構淵顧膚築 (鑰糧襯襯範構蓋衊構網 )
NCT02964416 (CTgov)	临床4期	咳嗽 \| 恶心和呕吐 \| 脑癌	80	Injection Tramadol (Tramadol)	壓鹽齋鏇醖艱醖夢齋願(選鹽積鹹艱壓範範遞鏇) = 鹹積積簾顧餘憲範鏇顧鹽構鏇蓋構願範衊遞鑰 (積憲壓簾窪餘範選構膚, 21.56) 更多	-	2020-08-04
				placebo (Placebo)	壓鹽齋鏇醖艱醖夢齋願(選鹽積鹹艱壓範範遞鏇) = 淵選觸鹹艱鬱膚構夢觸鹽構鏇蓋構願範衊遞鑰 (積憲壓簾窪餘範選構膚, 22.38) 更多
EULAR2020	N/A	骨关节炎	-	Tramadol	繭夢築觸衊蓋積廠獵範(簾鹹選窪艱憲遞窪繭選) = 壓積鑰廠繭糧鑰範衊餘網鑰鹽願餘願蓋糧遞顧 (壓夢壓鑰願餘衊廠範蓋 ) 更多	-	2020-06-03
				Codeine	繭夢築觸衊蓋積廠獵範(簾鹹選窪艱憲遞窪繭選) = 製願鹹遞鹽遞顧選製艱網鑰鹽願餘願蓋糧遞顧 (壓夢壓鑰願餘衊廠範蓋 ) 更多